Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation

NCT03539302 is registered in ClinicalTrials.gov with InCarda Therapeutics, Inc. as lead sponsor.

NCT NCT03539302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03539302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation
Lead sponsor
InCarda Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 29, 2018
Completion date
January 17, 2022
Enrollment
176 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation (paf)